Inhibition of angiogenesis by high molecular weight kininogen domain 3 peptide analogs
CA 2355287 A1 · Owner: Mccrae, Keith R. · Inventors: Mccrae, Keith R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Peptide analogs the high molecular weight kininogen domain (3) are potent inhibitors of angiogenesis. The peptides have the formula (a) X1-Asn-Asn-Ala- Thr-Phe-Tyr-Phe-Lys-X2, (b) X3-Cys-Val-Gly-Cys-X4 (c) X5-Leu-Asp-X7-Asn-Ala-, Glu-Val-Tyr-X6 or (d) Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-X7-Ser-Lys- Glu-Ser wherein: X1, X2, X3, X4, X5, and X6 are from zero to twelve amino acids, independently the same or different more preferably from zero to six , amino acids and; X7 is Ala or Cys. The peptides may also comprise biologically active fragments of high molecular weight kininogen domain (3). Methods of inhibiting endothelial cell proliferation and angiogenesis are provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 2, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 2, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 2, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.